Nisoldipine is a calcium channel blocker used as monotherapy or combined with other drugs for the treatment of hypertension. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation.
- Mechanism
- Curator reviewed
By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Nisoldipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
- Primary indication
- For the treatment of hypertension.Curator reviewed · 1 structured indication
- Formula / weight
- C20H24N2O6 · 388.4144 g/mol (avg)
- First approval
- United States, 1995
- Code names
- BAY-K-5552
- Brand names
Resolves to
VKQFCGNPDRICFG-UHFFFAOYSA-NSMILESCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OCC(C)CWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Nisoldipine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account